Marksans Pharma growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+1,027.0%	+16.8%
EBITDA	+1,038.4%	+21.0%
Net Income	+999.7%	+16.5%
EPS (adj.)	+994.0%	+16.2%
Total Assets	+1,093.8%	+20.8%
Total Equity	+1,128.4%	+20.0%
Free Cash Flow	+9,638.5%	+21.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+1027.0	+16.8
EBITDA	+1038.4	+21.0
Net Income	+999.7	+16.5
EPS (adj.)	+994.0	+16.2
Total Assets	+1093.8	+20.8
Total Equity	+1128.4	+20.0
Free Cash Flow	+9638.5	+21.2

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.